A custom-made vaccine with chemo and immune drugs for adults with glioblastoma
Original title: Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, and safety comes first.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a vaccine made for each patient, given with chemo and immune drugs.
Who this trial is for. This trial is for adults with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, a kind of brain tumor. It tests a treatment made for each patient, given with chemo and drugs that act on the immune system.
Where it stands. This trial has not reported any results. The first part checks safety and side effects. The next part compares the treatment with standard chemo. It measures how many people are alive at 12 months. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Nobody knows yet if this helps. It is a way to test a new mix of treatments. If you have glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary, you could ask your care team if a trial like this is worth looking into.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not proven care. Being in a trial is not a promise that you will get better. It is not a cure. Some people in a trial get the standard treatment instead. Side effects are still being studied.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.